お知らせ • Nov 20
LIDDS AB (publ) to Report Fiscal Year 2025 Final Results on May 06, 2026 LIDDS AB (publ) announced that they will report fiscal year 2025 final results on May 06, 2026 Reported Earnings • Sep 03
First half 2025 earnings released: kr0.015 loss per share (vs kr0.02 loss in 1H 2024) First half 2025 results: kr0.015 loss per share (improved from kr0.02 loss in 1H 2024). Net loss: kr2.04m (loss narrowed 15% from 1H 2024). お知らせ • Sep 03
LIDDS AB (publ) to Report Fiscal Year 2025 Results on Feb 19, 2026 LIDDS AB (publ) announced that they will report fiscal year 2025 results on Feb 19, 2026 お知らせ • Apr 26
LIDDS AB (publ), Annual General Meeting, May 28, 2025 LIDDS AB (publ), Annual General Meeting, May 28, 2025, at 10:00 W. Europe Standard Time. Location: at excore`s premises, at kungsportsavenyen 22, 411 36 gothenburg Sweden お知らせ • Nov 22
LIDDS AB (publ) to Report Fiscal Year 2024 Final Results on May 06, 2025 LIDDS AB (publ) announced that they will report fiscal year 2024 final results on May 06, 2025 お知らせ • Aug 28
LIDDS AB (publ) to Report Fiscal Year 2024 Results on Feb 20, 2025 LIDDS AB (publ) announced that they will report fiscal year 2024 results on Feb 20, 2025 お知らせ • May 31
LIDDS AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024 LIDDS AB (publ) announced that they will report nine months, 2024 results on Nov 21, 2024 お知らせ • May 29
LIDDS AB (publ) to Report First Half, 2024 Results on Aug 28, 2024 LIDDS AB (publ) announced that they will report first half, 2024 results on Aug 28, 2024 New Risk • May 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr27m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr22.7m market cap, or US$2.09m). お知らせ • Apr 19
LIDDS AB (publ), Annual General Meeting, May 27, 2024 LIDDS AB (publ), Annual General Meeting, May 27, 2024. お知らせ • Mar 22
LIDDS AB (publ) (OM:LIDDS) completed the acquisition of Noviga Research AB. LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB on January 29, 2024. The acquisition is subject to approval by the general meeting of LIDDS. The Board of Directors of LIDDS will convene an Extraordinary General Meeting to be held on 27 February 2024. The purchase price consists of newly issued shares in LIDDS in a ratio of 1:1, which means that the number of shares in LIDDS after the transaction amounts to 136,463,326 and value of the transaction is approximately SEK 16.2 million. As of February 27, 2024, LIDDS AB shareholders approved the transaction.
LIDDS AB (publ) (OM:LIDDS) completed the acquisition of Noviga Research AB on March 21, 2024. お知らせ • Jan 30
LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB. LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB on January 29, 2024. The acquisition is subject to approval by the general meeting of LIDDS. The Board of Directors of LIDDS will convene an Extraordinary General Meeting to be held on 27 February 2024. The purchase price consists of newly issued shares in LIDDS in a ratio of 1:1, which means that the number of shares in LIDDS after the transaction amounts to 136,463,326 and value of the transaction is approximately SEK 16.2 million. お知らせ • Jan 09
LIDDS AB (publ) Approves Board Elections LIDDS AB (publ) at its EGN held on January 9, 2024 approved election of Daniel Lifveredson, Torbjörn Browall and Lars-Inge Sjöqvist as ordinary board members, and Bengt Viterius as deputy board member. Daniel Lifveredson was elected as Chairman of the Board. お知らせ • Dec 15
LIDDS AB (publ) to Report Fiscal Year 2023 Final Results on Apr 23, 2024 LIDDS AB (publ) announced that they will report fiscal year 2023 final results at 12:00 PM, Central European Standard Time on Apr 23, 2024 お知らせ • Dec 07
Lidds AB (Publ) Announces Resignation of Daniel Lifveredson from Board of Directors LIDDS AB (publ) announces that Daniel Lifveredson has informed the company that he is leaving the board at his own request. The decision is based on disagreement about the company's strategic direction. The company's board therefore consists of Pontus Ottosson (chairman), David Bejker and Johan Lund. According to LIDDS' articles of association, the board must consist of a minimum of three and a maximum of ten members, and the board thus fulfills the requirements of the articles of association also after Daniel Lifveredson's resignation. Reported Earnings • Aug 31
First half 2023 earnings released: kr0.29 loss per share (vs kr0.58 loss in 1H 2022) First half 2023 results: kr0.29 loss per share (improved from kr0.58 loss in 1H 2022). Net loss: kr17.0m (loss narrowed 14% from 1H 2022). Revenue is expected to decline by 43% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 25%. お知らせ • Aug 01
LIDDS AB (publ) Announces CEO Changes LIDDS AB (publ) announced that Matthew Lindon will assume the role of acting Chief Executive Officer for LIDDS, effective August 1st, 2023, succeeding Anders Månsson. In addition to his role as Chief Scientific Officer for LIDDS, Matthew Lindon will take over the role as CEO on an interim basis from August 1st. Matthew joined LIDDS as CSO in March 2022 with over 20 years of drug discovery and development experience in global pharmaceutical R&D from AstraZeneca, GlaxoSmithKline and Merck. Over the last twelve months he has worked closely with out-going CEO, Anders Månsson to focus LIDDS' business and drive forward a strong business development strategy.Anders will remain with LIDDS until August 31st to ensure a smooth transition. New Risk • Jul 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr40m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr40m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (96% increase in shares outstanding). Revenue is less than US$1m (kr1.3m revenue, or US$123k). Market cap is less than US$10m (kr33.0m market cap, or US$3.06m). Reported Earnings • May 30
First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.29 loss in 1Q 2022) First quarter 2023 results: kr0.29 loss per share. Net loss: kr9.63m (loss narrowed 1.3% from 1Q 2022). Revenue is expected to decline by 17% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 26%. Reported Earnings • Mar 14
Full year 2022 earnings released: kr1.07 loss per share (vs kr1.16 loss in FY 2021) Full year 2022 results: kr1.07 loss per share (improved from kr1.16 loss in FY 2021). Net loss: kr36.9m (loss narrowed 1.1% from FY 2021). Revenue is expected to decline by 1.8% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 19%. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. お知らせ • Dec 09
LIDDS AB (publ) to Report Fiscal Year 2022 Results on Apr 25, 2023 LIDDS AB (publ) announced that they will report fiscal year 2022 results at 12:00 PM, Central European Standard Time on Apr 25, 2023 Reported Earnings • Nov 29
Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.26 loss in 3Q 2021) Third quarter 2022 results: kr0.23 loss per share. Revenue: kr1.19m (up 176% from 3Q 2021). Net loss: kr8.09m (loss widened 3.6% from 3Q 2021). Reported Earnings • Aug 29
Second quarter 2022 earnings released: kr0.29 loss per share (vs kr0.32 loss in 2Q 2021) Second quarter 2022 results: kr0.29 loss per share. Revenue: kr254.0k (up 71% from 2Q 2021). Net loss: kr9.91m (loss widened 1.5% from 2Q 2021). お知らせ • Aug 26
LIDDS AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023 LIDDS AB (publ) announced that they will report fiscal year 2022 results on Feb 24, 2023 Board Change • Jul 31
High number of new directors Independent Director Max Mitteregger was the last director to join the board, commencing their role in 2022. お知らせ • Jul 16
LIDDS AB (publ) Announces CEO Changes LIDDS AB (publ) announced that Anders Månsson will assume the role of Chief Executive Officer for LIDDS, effective September 1st 2022 succeeding Nina Herne. Anders Månsson has broad experience from leading roles both in the biotech sector and in larger multinational pharmaceutical companies in an international setting over 25 years. His substantial experience in business development from serving as e.g VP & Head of Global Business Development in LEO Pharma will be important for LIDDS in driving the value of current and future collaborations. Anders also has considerable experience from sales & marketing; he has been the Managing Director of a subsidiary in Ferring Pharmaceuticals, and he has headed a major global business unit in LEO Pharma. His experience also includes board-level and executive appointments in biotech companies, and most recently Anders was the CEO of RhoVac. Anders will join LIDDS September 1, 2022. Nina will remain as CEO until Anders is in place to secure a smooth transition. Nina is leaving LIDDS due to personal reasons. お知らせ • Jun 02
LIDDS AB (publ) Announces Board Changes LIDDS AB (publ) at it's annual general meeting held on 1 June 2022 resolved that Max Mitteregger and Johan Lund ware elected as new board members. Reported Earnings • May 25
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: kr0.29 loss per share (up from kr0.36 loss in 1Q 2021). Net loss: kr9.75m (loss narrowed 9.6% from 1Q 2021). Revenue missed analyst estimates by 100%. Earnings per share (EPS) also missed analyst estimates by 123%. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 19% per year. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Director David Bejker was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. お知らせ • Feb 24
LIDDS AB (publ) announced that it expects to receive SEK 40.8 million in funding from Nice & Green SA LIDDS AB (publ) announced that it has entered into an agreement for private placement of convertible notes for gross proceeds of SEK 40,800,000 on February 22, 2022. The transaction will include participation from Nice & Green SA. The company will receive funding in multiple tranches of SEK 10,200,000 each. The convertible notes have a maturity of 12 months and carries zero interest rate and can be converted into shares at a 7% discount. The transaction is subject to approval from extraordinary general meeting of the company. お知らせ • Feb 22
LIDDS AB Next Step with Nanozolid® Formulated Docetaxel LIDDS AB (publ) announced that the next step in the development of NanoZolid®-formulated docetaxel (nanodotax) will be to conduct a short clinical study to understand the immunological effects observed in the Phase I clinical study NZ-DTX-001. In the NZ DTX-001 study, activation of systemic inflammatory biomarkers was observed, which can provide improved conditions for treatment with so-called checkpoint inhibitors and result in treatment effect in non-injected tumors. In the clinical phase I study with nanodotax, which ended in October 2021, an activation of systemic inflammatory biomarkers was observed, which may open up the possibility of a combination therapy with so-called checkpoint inhibitors in cancer immunotherapy. Clinical studies have shown that systemically administered docetaxel significantly improves the response to treatment with checkpoint inhibitors. If LIDDS can show a similar effect with locally administered nanodotax but without systemic side effects, which risk inhibiting the specific immune response against the tumors, both improved efficacy and safety could be achieved. LIDDS has shown in preclinical studies that locally administered nanodotax has as good effect as systemically administered docetaxel but without systemic side effects. In order to provide a better foundation for decision-making in the clinical development of nanodotax, LIDDS has chosen to take over the sponsorship of the previously approved investigator driven trial on prostate cancer patients. The study provides an important analysis opportunity of the immunological response as the included patients will have their prostate surgically removed, which can be analyzed in detail. The study is planned to be conducted at one clinical site and is expected to include ten patients. お知らせ • Dec 30
LIDDS AB Announces Positive Topline Results from the Phase I Dose-Escalating Study of NanoZolid-Formulated Docetaxel LIDDS AB announced that the systemic exposure of docetaxel after treating solid tumors with NanoZolid-docetaxel is low and that the study demonstrated activity in both injected lesions and in systemic inflammatory markers. The results support further development of NanoZolid®-docetaxel In October 2021, LIDDS announced the closing of the NZ-DTX-001 Phase I study. It was demonstrated that NanoZolid® in combination with docetaxel was safe and well tolerated, reaching the primary endpoint of the trial. After further analysis it is also concluded that the systemic NanoZolid®-docetaxel exposure is low and that activity in injected lesions is observed. Patients receiving docetaxel showed activation of systemic inflammatory biomarkers including IFN-gamma, CXCL9 and CXCL10. These molecules are considered important for efficient recruitment and activation of immune effector cells and for creating a good environment for treatments with immune-modulating drugs such as check-point inhibitors. LIDDS intends to submit detailed study data for publication in a relevant journal. Recent Insider Transactions • Mar 07
Director recently bought kr159k worth of stock On the 5th of March, Daniel Lifveredson bought around 10k shares on-market at roughly kr15.90 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. お知らせ • Mar 04
LIDDS AB (publ) Enters R&D Agreement with Potential Exclusive, Global Product License Option LIDDS AB (publ) announced that an agreement has been signed with Johnson & Johnson Enterprise Innovation Inc. to develop an oncology product based on the NanoZolid® technology for an undisclosed indication. The flexibility of the NanoZolid® technology offers a possibility to develop controlled and sustained release of many different drugs for local application in cancer tumors which improves its efficacy and provides fewer injections and less side effects for the patients. Is New 90 Day High Low • Feb 26
New 90-day low: kr13.50 The company is down 4.0% from its price of kr14.05 on 27 November 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. お知らせ • Feb 26
LIDDS AB (publ) and Pharmidea Signs Manufacturing Agreement LIDDS AB (publ) announced that a collaboration agreement has been signed with PharmIdea SIA in Riga, Latvia. PharmIdea focuses on anti-cancer drugs and sterile formulations. The collaboration enables LIDDS to expand the manufacturing of new product candidates, e.g. including biomolecules and cytostatics, in addition to the already existing collaboration with Recipharm for Liproca Depot. LIDDS is preparing a clinical Phase I trial with intratumoral injections of NZ-TLR9 for treatment of solid tumors in patients with head/neck-, breast cancer, melanoma, sarcomas and lymphomas. The incidence of these cancers is more than 3 million patients yearly. The development of the NZ-TLR9 formulation will be the first project within the collaboration between LIDDS and PharmIdea. お知らせ • Feb 25
LIDDS Files Patent Application for Method to Treat Brain Cancer with Intratumoral Depot Injections LIDDS AB (publ) announced that a patent application related to NanoZolid® for treatment of brain cancers was filed to the European patent office. The patent application relates to a method to treat brain cancer with intratumoral depots providing a controlled drug release at the tumor site. Advances in treatments of malignant brain tumors have only modestly improved survival rates of patients. LIDDS can with the NanoZolid® technology expand its platform to brain cancer by circumventing the blood-brain barrier and to increase the drug distribution within the tumor area. The application describes treatment methods with NanoZolid® formulations that are administered transcranially with minimally invasive image guided injection techniques to form intratumoral depots that administer substances to the tumor while minimizing damage on the surrounding healthy brain tissue. The NanoZolid® technology can be applied to a large number of relevant active substances. お知らせ • Dec 19
LIDDS AB (publ) Provides Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot LIDDS AB (publ) announced that a newly revised guideline from the Chinese National Medical Products Administration (NMPA) has extended the requirements to a full registration dossier for the conditional market approval (CMA). LIDDS licensee Jiangxi Puheng Pharma is therefore aiming to submit the application for CMA for the prostate cancer drug candidate Liproca® Depot in China during first quarter, 2021. The CMA is a faster regulatory pathway for the approval of a medicine that addresses patients’ unmet medical needs based on less comprehensive data than is normally required. The prospect of Puheng Pharma registering Liproca® Depot in China, utilizing the CMA route, would shorten the time to market. Even without a direct approval of the CMA, the official introduction and communication with NMPA will promote the progress of the clinical program and subsequent market approval. お知らせ • Dec 17
LIDDS AB (publ) Announces Management Changes, Effective April 19, 2021 LIDDS AB (publ) announced that Nina Herne will assume the role of chief executive officer for LIDDS, effective April 19, 2021. Nina Herne has successfully held multiple senior positions in global pharmaceutical companies, most recently at Chiesi Group where she built a biotech operation and managed the company’s Swedish R&D site. Nina brings a wide range of experience from business development and licensing, R&D, operations, strategy development and international stakeholder management from smaller organizations like Zymenex (Managing Director for Sweden and Denmark) and NeuroNova, as well as larger companies like Chiesi, SOBI and NovoZymes (NovoNordisk).
Monica will remain as CEO until Nina is in place. Is New 90 Day High Low • Nov 13
New 90-day low: kr13.00 The company is down 12% from its price of kr14.80 on 14 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. Is New 90 Day High Low • Oct 29
New 90-day low: kr13.10 The company is down 6.0% from its price of kr13.95 on 30 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 6.0% over the same period. お知らせ • Sep 30
LIDDS AB (publ) Announces Data on Liproca Depot from Open Label Extension Study LIDDS AB (publ) announced results from the voluntary open-label extension (OLE) of LPC-004 in prostate cancer following the Liproca® Depot Phase IIb. Results showed that 50 % of the patients remained at low PSA levels for at least 10 months from their first Liproca® Depot injection and were therefore not treated with a second injection. PSA levels in the remaining six patients were in average reduced by 28% at 2 months post treatment and reduced PSA levels remained in 2 patients at the end of the study with PSA reductions of 43 % and 73 %. The voluntary OLE study involved twelve patients who participated in the Liproca® Depot Phase IIb clinical study. These were to receive a second Liproca® Depot injection, within 6-10 months from the initial injection, when their PSA levels had returned to the pre-study levels. 50 % of the patients (6 of 12) remained at low PSA levels for at least 10 months from their first Liproca® Depot injection and were therefore not treated with a second injection. The patients who received a second Liproca® Depot injection (6 of 12) were followed for another 6 months and their PSA levels were monitored. At 2 months post treatment, PSA levels were in average reduced by 28 %. PSA levels remained reduced over the full study period in 2 of the treated patients - PSA reductions were 43 % and 73 %, respectively. Is New 90 Day High Low • Sep 29
New 90-day high: kr16.15 The company is up 19% from its price of kr13.60 on 01 July 2020. The Swedish market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period. お知らせ • Jul 10
LIDDS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 37.083996 million. LIDDS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 37.083996 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 3,090,333
Price\Range: SEK 12
Transaction Features: Rights Offering